Dianthus Therapeutics is a clinical-stage biotech firm developing treatments for severe autoimmune conditions. The company's pipeline includes claseprubart, an engineered monoclonal antibody targeting active C1s complement protein with extended durability and enhanced effectiveness, and DNTH212, a fusion protein designed to reduce Type 1 interferon production through plasmacytoid dendritic cell inhibition while also suppressing B cell activity by blocking BAFF/APRIL signaling.

entry readiness 37 · WEAK SETUP · exit proximity 0

Value area 76.69–105.13 · 65% of 120d volume overhead · heavy supply